JAK抑制剂治疗斑秃患者的不良事件:系统综述
该系统综述检索PubMed、Embase和Cochrane数据库,纳入28篇文献(5项随机对照试验和23项病例系列),共1719例斑秃患者,评估6种JAK抑制剂的安全性。系统性JAK抑制剂耐受性良好,多数不良事件为轻度,因不良事件停药率低于安慰剂(1.6% vs 2.2%);实验室异常占口服JAK抑制剂相关不良事件的40.1%。
要点
- 系统性JAK抑制剂治疗斑秃耐受性良好,多数不良事件为轻度。
- 因不良事件停药率低于安慰剂(1.6% vs 2.2%)。
- 实验室异常占口服JAK抑制剂相关不良事件的40.1%。
核心结论
- 系统性JAK抑制剂治疗斑秃耐受性良好,多数不良事件为轻度,因不良事件停药率很低且在对照研究中低于安慰剂(1.6% vs 2.2%)。
- 未报告致命性结局。
研究设计与样本
- 于2022年8月18日进行的系统综述,检索PubMed、Embase和Cochrane数据库中斑秃与JAK抑制剂相关文献。
- 从407项检索研究中纳入28篇文献,包括5项随机对照试验和23项病例系列,共1719例患者,评估6种JAK抑制剂(巴瑞替尼、brepocitinib、deuruxolitinib、利特昔替尼、芦可替尼和托法替布)的安全性。
主要发现
- 系统性JAK抑制剂耐受性良好,多数不良事件为轻度,因不良事件停药率在对照研究中低于安慰剂(1.6% vs 2.2%)。
- 实验室异常占口服JAK抑制剂相关不良事件的40.1%,主要包括胆固醇、转氨酶、甘油三酯、肌酸磷酸激酶升高及散发性中性粒细胞减少/淋巴细胞减少。
- 其余不良事件涉及呼吸道(20.8%)、皮肤(17.2%)、泌尿生殖道(3.8%)或胃肠道(3.4%)。
- 感染率增加涉及上呼吸道(19.0%)、下呼吸道(0.3%)、泌尿生殖系统(3.6%)和皮肤(4.6%)。
- 报告了孤立性3至4级不良事件,包括心肌梗死、高血压急症、蜂窝织炎、横纹肌溶解、中性粒细胞减少和肌酸激酶高升高;未报告致命性结局。
关键数值与推荐
- 因不良事件停药率:1.6% vs 2.2%(对照研究中JAK抑制剂组 vs 安慰剂组)。
- 实验室异常占口服JAK抑制剂相关不良事件的40.1%。
- 不良事件分布:呼吸道20.8%、皮肤17.2%、泌尿生殖道3.8%、胃肠道3.4%。
- 感染率:上呼吸道19.0%、下呼吸道0.3%、泌尿生殖系统3.6%、皮肤4.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本综述的主要局限性是缺乏上市后监测数据,应长期维持上市后监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recently, the impressive efficacy of JAK-inhibitors (JAK-I) in alopecia areata (AA) has been described in several studies; however, to date, there is limited information on the safety of JAK-I in AA patients. For this reason, on 18 August 2022, a systematic review was performed to collect the premarketing and postmarketing data on the safety of JAK-I in patients treated for AA, evaluating for each molecule the reported adverse events (AEs) in indexed literature and their frequency. The keywords 'alopecia areata' AND 'Jak-inhibitors OR Janus-kinase Inhibitors' were searched on PubMed, Embase and Cochrane databases. Of 407 studies retrieved, 28 papers met the requirements and were used in our review, including five RCTs and 23 case series; overall, 1719 patients were included, and the safety of 6 JAK-I was assessed (baricitinib, brepocitinib, deuruxolitinib, ritlecitinib, ruxolitinib and tofacitinib). Systemic JAK-I were well-tolerated, most of the AEs were mild, and the withdrawal rate for AEs was very low and inferior to placebo in controlled studies (1.6% vs. 2.2%). Laboratory abnormalities represented 40.1% of AEs associated with oral JAK-I, which mostly included the rise in cholesterol, transaminase, triglycerides, creatine phosphokinase (CPK) and sporadic cases of neutro/lymphocytopenia. The remaining AEs involved the respiratory tract (20.8%), the skin (17.2%), the urogenital (3.8%), or the gastroenterological (3.4%) tract. Increased rates of infections involved not only the upper (19.0%) and lower (0.3%) respiratory tract, but also the urogenital system (3.6%) and the skin (4.6%). Isolated cases of grade 3 to 4 AEs have been reported, including myocardial infarction, hypertensive urgencies, cellulitis, rhabdomyolysis, neutropenia and high elevation of creatinine kinase. No fatal outcomes were reported. AEs reported with topical formulation included scalp irritation and folliculitis. The main limit of this review is the lack of data related to postmarketing surveillance, which should be maintained on a long-term basis.
引用
- Sechi A, Song J, Dell'Antonia M, et al. Adverse events in patients treated with Jak-inhibitors for alopecia areata: A systematic review. J Eur Acad Dermatol Venereol. 2023. PMID: 37013725. doi:10.1111/jdv.19090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。